Global Trademark Protection Secured Across Key Markets
Filed with ASX · · 2 pages · English
• Neurizon has secured registered trademark protection for NEURIZON® across all priority global markets, including the United States, the European Union, the United Kingdom, Australia and Japan • Completion of the US registration represents an important milestone supporting the Company’s long-term commercialisation strategy in its primary value-creation market • All registrations cover Class 42 se
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Regulatory and Development Update
- New Funding Secured for HEALEY ALS Platform Trial
- Equity Raising Presentation
- Trading Halt
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Later from Neurizon Therapeutics
- Neurizon Completes Entitlement Offer
- Neurizon secures $6million R&D Tax Incentive Rebate
- Appendix 4C & Quarterly Update
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics